Article Text

Correspondence on ‘EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs’
Free
  1. Serena Bugatti1,2,
  2. Silvia Balduzzi1,
  3. Ludovico De Stefano1,2,
  4. Antonio Manzo1,2,
  5. Blerina Xoxi1,
  6. Laura Bogliolo1,
  7. Sara Monti1,2,
  8. Paolo Delvino1,2,
  9. Carlomaurizio Montecucco1,2
  1. 1Division of Rheumatology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy
  2. 2Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
  1. Correspondence to Professor Serena Bugatti, Division of Rheumatology, IRCCS Policlinico San Matteo Foundation, Pavia 27100, Italy; serena.bugatti{at}unipv.it

Statistics from Altmetric.com

In light of their increased risk of worst outcomes following COVID-19 infection, patients with rheumatic and musculoskeletal diseases (RMDs) on immunosuppressive therapy, including systemic glucocorticoids, biological (b) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs), represent a vulnerable population which should be prioritised to receive vaccination. Controlled data on the effectiveness and safety of different COVID-19 vaccines on patients with RMD are not available yet. However, rheumatology providers and health professionals should be ready to offer timely guidance for the optimal use of vaccines for patients on immunomodulatory drugs. Based on the long-time experience with other non-live vaccines, the COVID-19 Task Force of the European League Against Rheumatisms (EULAR) first delivered a preliminary set of information in December 2020.1 Overall, it is expected that the safety and immunogenicity of COVID-19 vaccines for most of the DMARDs will be comparable with that registered for the general population,2–4 so that postponing vaccination pending more information appears unjustified. A number of independent surveys have however alarmingly reported that, among patients with RMD, potential acceptance of COVID-19 vaccines may not exceed 60%, without apparent differences in relation to specific diseases, comorbidities and type of medication.5–8 Strategies to effectively engage high-risk patients with RMD into vaccination programmes are therefore urgently needed.

Starting from 19 March 2021, rheumatologists of the IRCCS Policlinico San Matteo University Hospital of Pavia, Italy, have been actively involved in the vaccination campaign by personally contacting, booking and administering COVID-19 vaccines to patients with RMD on b/tsDMARDs followed at our institution. In course of phone contacts, rheumatologists identify themselves and offer a vaccination date. In agreement with the most recent determination of the Italian Ministry of Health (https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2021&codLeg=79076&parte=1&serie=null), patients are informed that they will receive alternatives to Oxford–AstraZeneca; the vaccine currently available at our hospital is the Pfizer/BioNTech. On the day of vaccination, patients are asked on their potential acceptance of other COVID-19 vaccines (Oxford–AstraZeneca, Moderna, Johnson & Johnson). Demographic and clinical characteristics are retrieved from electronic records and are detailed in online supplemental table 1. All patients provide their informed consent for the use of their anonymous data.

The general restrictions in vaccine supply are impacting on the rate of recruitment, with 224 patients out of a total cohort of ~900 having been contacted in the first 15 days of the campaign. Twenty-three patients (10.3%) opposed to vaccination despite extensive counselling; 23 (10.3%) had already been vaccinated (91.3% with Pfizer/BioNTech); 8 (3.5%) had recovered from COVID-19 for <3 months and, in agreement with the rheumatologist, postponed vaccination of 3 months; 35 (15.6%) expressed initial hesitancy but accepted vaccination following rheumatologists’ recommendations; 135 (60.3%) immediately endorsed the vaccination proposal. Collectively, adhesion to vaccination was thus spontaneous in 70.5% of the cases (23 already vaccinated+135 agreeing to vaccinate irrespective of the rheumatologist), a proportion that increased to 89.7% (n=201) following rheumatologists’ recommendations in recent COVID-19 and hesitant patients. Of the 201 patients who received at least the first dose or were willing to do so, 154 (76.6%) would have accepted any vaccine, 24 (11.9%) any apart from Oxford–AstraZeneca, 12 (6%) Pfizer/BioNTech only, and 11 (5.5%) were uncertain but ready to follow rheumatologists’ advice. As a result, despite active involvement of rheumatologists, potential adherence to vaccines alternative to Pfizer/BioNTech was significantly lower (73.7% vs 89.7%, p<0.001). As shown in table 1, factors associated with acceptance of Pfizer/BioNTech were mostly related to the intensity of immunosuppression, with a significant impact of combination therapy with conventional synthetic DMARDs, a trend for higher odds for prednisone doses ≥5 mg/day and lower odds for rituximab. In contrast, factors conditioning individual preferences among vaccines were predominantly demographic, with women of younger age (<50 years) and higher body mass index (>30) more frequently expressing scepticism towards alternatives to Pfizer/BioNTech.

Table 1

Factors associated with adhesion to COVID-19 vaccination

As real-world experience accumulates, it is not surprising that the spontaneous acceptance of COVID-19 vaccination found here is higher compared with previous studies.5–8 However, active involvement of rheumatologists may further engage hesitant patients, allowing coverage of nearly 90% of those receiving several immunomodulatory drugs in combination. In this perspective, the constitution of dedicated task forces, such as those promoted by EULAR1 as well as by other national and international societies,9 10 is fundamental to assist rheumatology providers with updated guidelines on the optimal use of COVID-19 vaccines for patients with RMD. The treating rheumatologists should then be at the fore of outreach strategies aimed at engaging as many patients with RMD as possible among those followed at their centres. Still, misinformation about individual characteristics potentially affecting the efficacy and adverse reactions of different vaccines may introduce delays in a proportion of immunosuppressed patients11 for whom efforts of the treating rheumatologists are unlikely to produce significant effects in the absence of forceful public campaigns.

Data availability statement

The authors confirm that the data supporting the findings of this study are available within the article. Raw data are available from the corresponding author (SBu) upon reasonable request.

Ethics statements

Ethics approval

The study was approved by the Local Ethical Committee of the IRCCS Policlinico San Matteo Foundation, Pavia, Italy.

Acknowledgments

We are grateful to our trainees Dr Fabio Brandolino, Dr Sofia Chiricolo, Dr Bernardo D’Onofrio, Dr Michele Di Lernia, Dr Eleonora Mauric, Dr Alessandra Milanesi and Dr Clarissa Rocca. We are grateful to our nurses Laura Vecchio, Marina Berlinese, Michela Milanesi and Massimo Facchini.

References

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Footnotes

  • Contributors SBu conceived the work, contributed to the analysis and interpretation of data, and drafted the manuscript. SBa contributed to the acquisition and interpretation of data and revised the manuscript critically for important intellectual content. LDS contributed to the acquisition and interpretation of data and revised the manuscript critically for important intellectual content. AM conceived the work, contributed to the interpretation of data and revised the manuscript critically for important intellectual content. BX contributed to the acquisition of data and revised the manuscript critically for important intellectual content. LB contributed to the acquisition of data and revised the manuscript critically for important intellectual content. SM contributed to the acquisition of data and revised the manuscript critically for important intellectual content. PD contributed to the acquisition of data and revised the manuscript critically for important intellectual content. CM conceived the work and revised the manuscript critically for important intellectual content. All the authors provided final approval of the version to be published.

  • Funding This study was supported in part by fundings from the IRCCS Policlinico San Matteo Foundation, Pavia, Italy.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles